MedTrace Logo

Study Investigating the Efficacy and Safety of a Contraceptive Patch for 13 Cycles

NCT00910637 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1502

Last updated 2021-04-08

No results posted yet for this study

Summary

This study is examining a birth control patch for 13 cycles (1 year).

Conditions

  • Contraception

Interventions

DRUG

Gestodene/EE Patch (BAY86-5016)

55 mg ethinyl estradiol \& 2.1 mg gestodene, 21 days for 13 cycles

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-05-01
Primary Completion
2010-12-13
Completion
2010-12-13

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00910637 on ClinicalTrials.gov